Drug Trial Radar · NCT04890587
A Phase I Study of AL8326 in Advanced Solid Tumor
Last checked: Nov 19, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 17, 2017
Primary completion
Dec 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Advenchen Laboratories Nanjing Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. Main purpose Objective to study the tolerance and safety of single and multiple administration of repeated 28-day cycles of AL8326 in patients with advanced solid tumor, observe the dose limiting toxicity (DLT) and maximum tolerated dose (MTD). 2. Secondary purpose 1) Preliminary analysis of the pharmacokinetic characteristics and efficacy of repeated 28-day cycles of AL8326 tablets in patients with advanced solid tumors; 2) According to the results of phase I tolerance test and pharmacokinetics, appropriate dosage and regimen were recommended for phase II clinical trial;
Conditions
- Advanced Solid Tumors
Interventions
AL8326 tabletsDrug
Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: cycle1 (each cycle is 28-days)
- Maximum tolerated dose (MTD)Time frame: cycle1 (each cycle is 28-days)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.